<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01575730</url>
  </required_header>
  <id_info>
    <org_study_id>2012/237</org_study_id>
    <secondary_id>2012-000701-77</secondary_id>
    <nct_id>NCT01575730</nct_id>
  </id_info>
  <brief_title>Cytoreduction Followed by Normothermic Versus Hyperthermic Intraperitoneal Intraoperative Chemoperfusion (HIPEC): a Study in Peritoneal Carcinomatosis</brief_title>
  <official_title>Phase II Study Comparing Normothermic Versus Hyperthermic Intraoperative Chemoperfusion With Oxaliplatin in Patients With Peritoneal Metastases From Appendiceal or Colon Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peritoneal carcinomatosis from appendix or colon (large bowel) cancer is treated in suitable
      patients with surgery followed by instillation of heated chemotherapy inside the abdominal
      cavity. This procedure is termed 'Hyperthermic intraoperative Peritoneal Chemoperfusion' or
      HIPEC. Many center perform HIPEC with high dose oxaliplatin, a standard chemotherapy drug
      active against colon cancer, administered during 30 minutes at 41°C. The hypothesis of this
      study is, that chemoperfusion at normal (37.5°C) temperature but longer duration (90 minutes)
      may be safer and at least as efficient. Patients will be treated with one of three possible
      HIPEC regimens using oxaliplatin: high dose, 30 min, 41°C; high dose, 30 min, 37.5°C; or low
      dose, 90 min, 37.5°C. The outcome parameters are pharmacokinetic and pharmacodynamic: using
      specialized techniques, tissue penetration of chemotherapy and cancer cell kill effects will
      be compared in order to establish the safest and most active HIPEC regimen.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morbidity</measure>
    <time_frame>Until discharge or within 30 days</time_frame>
    <description>Scoring of postoperative morbidity according to the Dindo-Clavien system</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>Until discharge or within 30 days</time_frame>
    <description>The number of deaths will be recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the perfusate concentration versus time curve (AUC) of platinum</measure>
    <time_frame>Before addition of chemotherapy, at 10, 20 and 30 minutes after addition of chemotherapy</time_frame>
    <description>Measurements of platinum in perfusate samples on the high dose interventions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the perfusate concentration versus time curve (AUC) of platinum</measure>
    <time_frame>Before addition of chemotherapy, at 10, 20, 30, 40, 50, 60, 70, 80 and 90 minutes after addition of chemotherapy</time_frame>
    <description>Measurements of platinum in perfusate samples on the low dose intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of platinum</measure>
    <time_frame>Before addition of chemotherapy, at 10, 20, 30,45, 60, 90 minutes and 2, 4, 8, 12, 18, 24 hours after addition of chemotherapy</time_frame>
    <description>Measurements of platinum in perfusate samples on the high dose interventions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of platinum</measure>
    <time_frame>Before addition of chemotherapy, at 10, 20, 30, 40, 50, 60, 70, 80, 90 minutes and 2, 4, 8, 12, 18, 24 hours after addition of chemotherapy</time_frame>
    <description>Measurements of platinum in plasma samples on the low dose intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tissue Concentration (Cmax) of Platinum</measure>
    <time_frame>after 30 or 90 minutes</time_frame>
    <description>Platinum concentration will be measured after removal of perfusate.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Peritoneal Carcinomatosis</condition>
  <arm_group>
    <arm_group_label>Oxaliplatin 37°C, high dose, 30 minutes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxaliplatin 41 °C, high dose, 30 minutes</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxaliplatin 37°C, low dose, 90 minutes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hyperthermic intraoperative Peritoneal Chemoperfusion</intervention_name>
    <description>Dose: 460 mg/m², duration: 30 minutes, temperature 37°C</description>
    <arm_group_label>Oxaliplatin 37°C, high dose, 30 minutes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hyperthermic intraoperative Peritoneal Chemoperfusion</intervention_name>
    <description>Dose: 460 mg/m², duration: 30 minutes, temperature 41°C</description>
    <arm_group_label>Oxaliplatin 41 °C, high dose, 30 minutes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperthermic intraoperative Peritoneal Chemoperfusion</intervention_name>
    <description>Dose: 200 mg/m², duration: 90 minutes, temperature 37°C</description>
    <arm_group_label>Oxaliplatin 37°C, low dose, 90 minutes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with peritoneal carcinomatosis from colorectal origin (including appendiceal
             mucinous neoplasms and the pseudomyxoma syndromes) amenable for cytoreduction and
             HIPEC.

        Exclusion Criteria:

          -  No written informed consent

          -  Irresectable and/or metastatic disease found during surgery

          -  Known allergy to oxaliplatin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wim P Ceelen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wim P Ceelen, MD, PhD</last_name>
      <email>wim.ceelen@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Wim P Ceelen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.uzgent.be</url>
    <description>Related Info</description>
  </link>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2012</study_first_submitted>
  <study_first_submitted_qc>April 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2012</study_first_posted>
  <last_update_submitted>December 4, 2014</last_update_submitted>
  <last_update_submitted_qc>December 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peritoneal carcinomatosis from colorectal or appendiceal origin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

